Latest 8-K filings

BK Technologies announced double-digit revenue growth, expanded gross margins to 51.9%, and a record cash balance of $29.9 million for Q2 FY26.

Comstock Holding Companies, Inc. announced robust second quarter 2026 financial results, featuring a 74% surge in revenue to $22.6 million and a 512% increase in net income.

Saga Communications, Inc. announced a 6.5% decrease in net revenue for Q2 2026 to $26.4 million and a net loss of $1.4 million for the six-month period.

SINTX Technologies announced it has regained compliance with Nasdaq's minimum stockholders equity requirement, closing a previously disclosed deficiency matter.

OptimumBank Holdings announced record second-quarter 2026 earnings, surpassing $1.4 billion in total assets, driven by a relationship-based banking strategy and disciplined credit culture.

Biofrontera Inc. announced robust second quarter 2026 financial results, highlighted by a 32.9% increase in net product revenue to $12.0 million and a significant improvement in gross margin to 80%.

RenX Enterprises Corp. announced record second-quarter 2026 revenue of $4.26 million, driven by sequential growth in its two primary operating segments, alongside continued profitability in its Logistics segment.

Lifeway Foods announced record-breaking quarterly net sales of $66.9 million, marking the 27th consecutive quarter of year-over-year growth, despite facing temporary margin headwinds from elevated milk and packaging costs.

Aeternum Health has acquired an option to purchase a 51% stake in the Nkamouna Nickel-Cobalt-Manganese mining project in Cameroon, signaling a strategic move into critical mineral production.

Dogwood Therapeutics announced its second quarter 2026 financial results, highlighting progress in its Halneuron Phase 2b trial and a new development partnership, while also reporting a substantial non-cash impairment charge.

Bed Bath & Beyond, Inc. announces the appointment of Jill Windrum as Chief Accounting Officer and Deputy Chief Financial Officer, effective August 31, 2026.

Cingulate Inc. announced its second quarter 2026 financial results, highlighting $28.4 million in cash, progress on CTx-1301 manufacturing, and a new patent, while navigating a delayed NDA resubmission.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101 and reporting a net loss of $9.8 million for Q2 2026.

Ovid Therapeutics reported Q2 2026 business updates and financial results, highlighting progress in its OV4071 and OV329 programs, a strategic soticlestat transaction, and strengthened leadership.

Fate Therapeutics announced second quarter 2026 financial results, highlighting progress in its CAR T-cell therapy pipeline, including patient dosing in a Phase 2 trial for lupus nephritis and FDA clearance for a new autoimmune trial.

HeartCore Enterprises announced second quarter 2026 financial results, showing a 71.6% revenue increase to $321,000 but a net loss of $2.0 million, a significant shift from the prior year's net income.

Tron Inc. announced a strategic initiative to deepen its integration with the TRON DAO ecosystem and pursue Super Representative status, aiming to generate recurring on-chain revenue.

FitLife Brands reported a 65% revenue increase in Q2 2026, largely due to the Irwin Naturals acquisition, alongside sequential growth and improved EPS.

SS Innovations International announced record second quarter 2026 revenue of $13.9 million, a 39.4% increase year-over-year, driven by strong sales of its SSi Mantra surgical robotic system.

Banzai International, Inc. has issued a new Senior Secured Convertible Note with an original principal amount of $1,099,989.00, convertible into shares of common stock.

Ondas Inc. announced record Q2 2026 revenue of $83.8 million, a 67% sequential increase and 13-fold year-over-year growth, while raising its full-year revenue target to $525-$550 million.

Sonida Senior Living, Inc. has entered into a new $380.0 million senior secured term loan with Ally Bank, amending and restating its existing agreement.

Lucid Diagnostics announced second quarter 2026 financial results, reporting $1.5 million in revenue and processing 2,770 EsoGuard tests, while also securing a key laboratory benefit manager coverage policy.

SPAR Group, Inc. announced its second quarter fiscal 2026 financial results, reporting a return to profitability with positive net income and increased Adjusted EBITDA, despite a year-over-year revenue decrease.

NeuroOne Medical Technologies Corporation announced a 16% year-over-year increase in product revenue to $2.0 million for its third fiscal quarter ended June 30, 2026, alongside a significant expansion in gross margins to 59.9%.

Candel Therapeutics announced Q2 2026 results, highlighting progress in its aglatimagene prostate cancer program with a planned BLA submission in Q4 2026 and positive Phase 3 data published in The Lancet Oncology.

Pulmatrix announces Q2 2026 results, highlighting progress on its merger with Eos Senolytix and efforts to out-license or monetize its clinical assets.

Solo Brands announced its fiscal 2026 second quarter results, highlighting improved profitability and significant debt reduction despite a dip in net sales.

MeiraGTx reports strong Q2 2026 results, highlighted by the acquisition of botaretigene sparoparvovec, a $400 million strategic investment, and positive clinical data for AAV2-hAQP1.

Duke Robotics Corp. announced its second quarter 2026 financial results, highlighting an expanded Israel Electric Corporation contract, a new defense order, and a successful $9.2 million public offering and Nasdaq uplisting.